Sign up USA
Proactive Investors - Run By Investors For Investors

XBiotech knocked hard by negative European cancer ruling

The Austin-based company was notified of a negative trend decision by the EMA
picture of cells
XBiotech said it was disappointed by the EMA indication

XBiotech Inc (NASDAQ:XBIT) crashed by 40% as the European Medicines Agency knocked back its colorectal cancer treatment antibody.

The Austin-based company was notified of a negative trend decision by the EMA, which makes it unlikely that a recommendation for use in humans would be received at the formal decision vote scheduled in May and additional steps to gain marketing approval are necessary.

John Simard, chief executive, said the company was disappointed.

“We believe that the data speak in a clear and resounding voice to clinical relevance of a new antibody therapy in advanced colorectal cancer.

"Findings from our Phase III study show that we have developed an important endpoint and methodology to evaluate anti-cancer therapy in advanced stage disease and that our monoclonal antibody represents a breakthrough treatment in patients with advanced colorectal cancer.”

An appeal is possible and Simard said as the decision was based on an oral meeting the company may go down this route 'at the appropriate time'.

XBiotech had been a strong performer ahead of the decision but its share price dropped US$6.80 to US$10.30 today.

PhilW.jpg


Register here to be notified of future XBIT Company articles
View full XBIT profile

XBiotech Timeline

Related Articles

stylised picture with web icons meant to denote a web search
May 11 2016
Searchbolt, the business being bought, was spun-off from ETX when the latter was listed on stock market in 2007
GW_Pharma.png
January 11 2017
“[We are] entering a very exciting phase, which should result in the crystallisation of substantial value,” said chief executive, Dr Satu Vainikka.
viagra2.jpg
September 07 2016
It means Futura now has a differentiated product in a market worth US$5bn that , currently dominated by top-selling drugs, such as Viagra and Cialis, that have limitations.
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use